Tianyu Co., Ltd. announced that Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for tigletine hydrobromide tablets approved and issued by the State Drug Administration. The registration classification is 4 types of chemicals, with a specification of 20 mg. The indication is to improve blood sugar control in adult type 2 diabetics with diet control and exercise. As of September 30, 2026, the company and its subsidiaries have invested a total of about 5.9742 million yuan in research and development of this variety. After approval, the drug can be manufactured and sold domestically, which will enrich the company's formulation variety and have a positive impact on business performance, but there is uncertainty about its future production, sales and profit levels.

Tianyu Co., Ltd. announced that Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for tigletine hydrobromide tablets approved and issued by the State Drug Administration. The registration classification is 4 types of chemicals, with a specification of 20 mg. The indication is to improve blood sugar control in adult type 2 diabetics with diet control and exercise. As of September 30, 2026, the company and its subsidiaries have invested a total of about 5.9742 million yuan in research and development of this variety. After approval, the drug can be manufactured and sold domestically, which will enrich the company's formulation variety and have a positive impact on business performance, but there is uncertainty about its future production, sales and profit levels.